Biogen Inc. (BIIB)
BIIB Stock Price Chart
Explore Biogen Inc. interactive price chart. Choose custom timeframes to analyze BIIB price movements and trends.
BIIB Company Profile
Discover essential business fundamentals and corporate details for Biogen Inc. (BIIB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
17 Sept 1991
Employees
7.61k
Website
https://www.biogen.comCEO
Christopher A. Viehbacher
Description
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
BIIB Financial Timeline
Browse a chronological timeline of Biogen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is $3.13, while revenue estimate is $2.46bn.
Earnings released on 29 Apr 2026
EPS came in at $3.57 surpassing the estimated $3.05 by +17.05%, while revenue for the quarter reached $2.48bn , beating expectations by +8.35%.
Earnings released on 6 Feb 2026
EPS came in at $1.99 surpassing the estimated $1.63 by +22.09%, while revenue for the quarter reached $2.28bn , beating expectations by +3.48%.
Earnings released on 30 Oct 2025
EPS came in at $4.81 surpassing the estimated $3.88 by +23.97%, while revenue for the quarter reached $2.45bn , beating expectations by +4.91%.
Earnings released on 31 Jul 2025
EPS came in at $5.47 surpassing the estimated $3.90 by +40.26%, while revenue for the quarter reached $2.65bn , beating expectations by +13.63%.
Earnings released on 1 May 2025
EPS came in at $3.02 surpassing the estimated $2.90 by +4.14%, while revenue for the quarter reached $2.43bn , beating expectations by +8.81%.
Earnings released on 12 Feb 2025
EPS came in at $3.44 surpassing the estimated $3.43 by +0.29%, while revenue for the quarter reached $2.45bn , beating expectations by +1.93%.
Earnings released on 30 Oct 2024
EPS came in at $4.08 surpassing the estimated $3.77 by +8.22%, while revenue for the quarter reached $2.47bn , beating expectations by +1.29%.
Earnings released on 1 Aug 2024
EPS came in at $5.28 surpassing the estimated $4.07 by +29.73%, while revenue for the quarter reached $2.35bn , missing expectations by -1.65%.
Earnings released on 24 Apr 2024
EPS came in at $3.67 surpassing the estimated $3.47 by +5.76%, while revenue for the quarter reached $2.29bn , missing expectations by -0.80%.
Earnings released on 13 Feb 2024
EPS came in at $2.95 falling short of the estimated $3.16 by -6.65%, while revenue for the quarter reached $2.39bn , missing expectations by -3.19%.
Earnings released on 8 Nov 2023
EPS came in at $4.36 surpassing the estimated $3.99 by +9.27%, while revenue for the quarter reached $2.53bn , beating expectations by +5.88%.
Earnings released on 25 Jul 2023
EPS came in at $4.02 surpassing the estimated $3.77 by +6.63%, while revenue for the quarter reached $2.46bn , beating expectations by +3.66%.
Earnings released on 25 Apr 2023
EPS came in at $3.40 surpassing the estimated $3.28 by +3.66%, while revenue for the quarter reached $2.46bn , beating expectations by +5.17%.
Earnings released on 15 Feb 2023
EPS came in at $4.05 surpassing the estimated $3.48 by +16.38%, while revenue for the quarter reached $2.54bn , beating expectations by +4.04%.
Earnings released on 25 Oct 2022
EPS came in at $4.77 surpassing the estimated $4.13 by +15.50%, while revenue for the quarter reached $2.51bn , beating expectations by +1.60%.
Earnings released on 20 Jul 2022
EPS came in at $5.25 surpassing the estimated $4.06 by +29.31%, while revenue for the quarter reached $2.59bn , beating expectations by +4.66%.
Earnings released on 3 May 2022
EPS came in at $3.62 falling short of the estimated $4.41 by -17.91%, while revenue for the quarter reached $2.53bn , beating expectations by +1.28%.
Earnings released on 3 Feb 2022
EPS came in at $3.39 surpassing the estimated $3.32 by +2.11%, while revenue for the quarter reached $2.73bn , beating expectations by +4.34%.
Earnings released on 20 Oct 2021
EPS came in at $4.77 surpassing the estimated $4.15 by +14.94%, while revenue for the quarter reached $2.78bn , beating expectations by +4.07%.
Earnings released on 22 Jul 2021
EPS came in at $5.68 surpassing the estimated $4.57 by +24.29%, while revenue for the quarter reached $2.78bn , beating expectations by +3.73%.
BIIB Stock Performance
Access detailed BIIB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
